The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
2020 · Signal Transduction and Targeted Therapy · 131 citations
https://doi.org/10.1038/s41392-020-00256-x
C
Chunmeng Wang
Chinese Academy of Medical Sciences & Peking Union Medical College(CN)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
57
Papers
2.2K
Citations
19
h-index
26
i10-index
Chunmeng Wang is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: CAR-T cell therapy research & Lymphoma Diagnosis and Treatment & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 19, co-authored 49 publications.
ORCID: 0009-0005-5915-1393Papers by this author
worksTreatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
2016 · Signal Transduction and Targeted Therapy · 130 citations
https://doi.org/10.1038/sigtrans.2016.2
Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
2021 · Journal of Hematology & Oncology · 30 citations
https://doi.org/10.1186/s13045-021-01120-3
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
2020 · Journal of Hematology & Oncology · 11 citations
https://doi.org/10.1186/s13045-020-00878-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat